Posted by Michael Wonder on 06 Mar 2019
Patient advocacy groups in Canada with ties to pharma are big boosters for government coverage
5 March 2019 - As the interplay between the pharmaceutical industry and patient advocacy groups undergoes stepped-up scrutiny, a new analysis finds a large majority of Canadian groups that submitted comments about pending government coverage for medicines also held conflicts with drug makers.
Specifically, 87% of comments were made by Canadian groups that had a conflict of interest, such as industry backing.
And of those comments, 86% involved a conflict with the drug maker that was marketing the medicine being reviewed by the Common Drug Review and panCanadian Oncology Drug Review.
